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Abstract
Fingolimod is an approved oral treatment for relapsing–remitting multiple sclerosis (RRMS) that modulates agonistically the 
sphingosin-1-phosphate receptor (S1PR), inhibiting thereby the egress of lymphocytes from the lymph nodes. In this interven-
tional prospective clinical phase IV trial, we longitudinally investigated the impact of fingolimod on frequencies of NK cell 
subpopulations by flow cytometry in 17 RRMS patients at baseline and 1, 3, 6, and 12 months after treatment initiation. Clini-
cal outcome was assessed by the Expanded Disability Status Scale (EDSS) and annualized relapse rates (ARR). Over the study 
period, median EDSS remained stable from month 3 to month 12, and ARR decreased compared to ARR in the 24 months 
prior treatment. Treatment was paralleled by an increased frequency of circulating NK cells, due primarily to an increase in 
 CD56dimCD94low mature NK cells, while the  CD56bright fraction and  CD127+ innate lymphoid cells (ILCs) decreased over 
time. An unsupervised clustering algorithm further revealed that a particular fraction of NK cells defined by the expression 
of  CD56dimCD16++KIR+/−NKG2A−CD94−CCR7+/−CX3CR1+/−NKG2C−NKG2D+NKp46−DNAM1++CD127+ increased 
during treatment. This specific phenotype might reflect a status of aged, fully differentiated, and less functional NK cells. 
Our study confirms that fingolimod treatment affects both NK cells and ILC. In addition, our study suggests that treatment 
leads to the enrichment of a specific NK cell subset characterized by an aged phenotype. This might limit the anti-microbial 
and anti-tumour NK cell activity in fingolimod-treated patients.
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Introduction
Multiple sclerosis (MS) is one of the most frequent chronic 
neurological diseases in young adults in western countries 
[1]. MS is traditionally considered a primarily demyelinat-
ing autoimmune disease [2–4], in which autoreactive  CD4+ 
T cells play a key role in the initiation and maintenance of 
the chronic inflammation within the central nervous sys-
tem [5]. This inflammatory process, also supported by B 
cells and macrophages, eventually leads to demyelination, 
axonal damage [6] and loss of neurological functions [7].
Fingolimod (Gilenya®) is approved as oral treatment 
for relapsing–remitting (RR) MS [8, 9]. Its efficacy could 
be demonstrated in different phase III studies [10–13]. 
Fingolimod acts by withholding lymphocytes within the 
lymph nodes through the modulation of the sphingosin-
1-phosphate (S1P) receptor [14]. Specifically, fingolimod 
is an agonist of the  S1P1 and  S1P3-5 receptors that are 
expressed on lymphocytes and regulate cell trafficking [14] 
as well as vascular barrier function [15, 16], angiogenesis 
[17], and vascular tone [18]. After its binding, it leads 
to hyperactivation and subsequently internalization of the 
receptor, which results in an inhibition of lymphocytic 
egress from the lymph nodes [19–21] and modulation of 
the profile of circulating immune cells [22]. S1P receptors 
are also expressed on innate lymphocytes (ILCs), includ-
ing NK cells [23–25].
Classically, human NK cells are subdivided according 
to their CD56 expression into  CD56bright and  CD56dim NK 
cells [26]. Approximately 90% of the peripheral NK cells 
in circulation are  CD56dim, whereas  CD56bright NK cells 
are more abundant in secondary lymphoid tissues and 
within the cerebrospinal fluid [27–29].
To date, both beneficial and deleterious roles of NK 
cells have been proposed in MS [30–33]. Reports of the 
last four decades indicate that MS development is associ-
ated with a deficient NK cell activity [34–41]. However, 
other studies showed a relationship between NK cell action 
and central nervous system pathology [42–47], indicating 
that the effect of NK cells on MS may depend on the NK 
cell type or mode of action.
Treatment-related enrichment of a particular NK cell 
subset, mostly  CD56bright, or induction of NK cell acti-
vation has been associated with the therapeutic success 
of numerous MS drugs including interferon-beta, dacli-
zumab, mitoxantrone, glatiramer acetate, or alemtuzumab 
[36, 48–59].
Effects of fingolimod on NK cells have also been 
extensively investigated [22, 52, 60–70]. Apart from one 
study that did not observe any significant effect of fin-
golimod on NK cells [22], all other cross-sectional stud-
ies have shown a relative increase of NK cells compared 
with other lymphocyte populations. These studies also 
revealed a decrease of  CD56bright in comparison to 
 CD56dim in fingolimod-treated patients compared with an 
untreated cohort, healthy controls, or patients treated with 
other medications [60, 61, 64]. Interestingly, although 
proportions but not absolute numbers of NK cells and 
 CD56dim were affected by fingolimod treatment, signifi-
cant reduction in  CD56bright counts was observed [63, 67, 
68, 71]. Longitudinal intra-individual studies corrobo-
rated the altered frequencies of NK cells and  CD56bright 
and  CD56dim [62, 64, 65, 68, 69]. However, the specific 
immune profiles of these enriched or depleted subpopula-
tions remain largely undetermined.
In a more recent publication, Eken et al. [25] showed 
a decrease of all types of ILCs in the peripheral blood of 
fingolimod-treated patients comparing off and on treatment.
It has been demonstrated that the expression of S1P 
receptors increases during NK cell maturation [24]. Thus, 
different NK cell subtypes may respond differently to S1P-
receptor agonist such as fingolimod.
Therefore, in this study, we aimed to investigate longitu-
dinally the effects of fingolimod on NK cell homeostasis and 
maturation/differentiation to define more comprehensively 
the profile of NK cells enriched under fingolimod therapy. 
We hypothesized that fingolimod specifically targets certain 




A post-authorizational investigator-driven, interventional, 
prospective, open-label, baseline-to-treatment study 
was designed to evaluate the effects of fingolimod treat-
ment on NK cells in RRMS patients. The study (Eudra-
CT:2012–000,411-91; NCT 01790269) was approved by 
the responsible ethics committee (Approval ID: 12/9543-
EK) and regulative authorities and was conducted in accord- 
ance with the Declaration of Helsinki, the guidelines of the 
International Conference on Harmonization of Good Clini-
cal Practice, and the applicable German laws. All partici- 
pants gave informed written consent. Patients were screened 
and enrolled at the Experimental and Clinical Research 
Center and the Neurocure Research Center at Charité-
Universitätsmedizin Berlin. The main inclusion criteria 
were RRMS according to the 2010 McDonald criteria [72] 
with an Expanded Disability Status Scale (EDSS) ≤ 6.0 
[73], age 18–64 years, an indication for on-label treatment 
with fingolimod, and absence of relapse for 30 days prior 
to screening. Exclusion criteria were mainly related to the 
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contraindications of fingolimod as indicated in the label. An 
additional exclusion criterion was the intake of other disease 
modifying drugs within 6 months (regarding mitoxantrone, 
azathioprine, or any other immunosuppressive drug except 
prednisolone) or 3 months (natalizumab) prior to baseline. 
Detailed inclusion and exclusion criteria are provided as 
supplementary Table 1.
Effects of fingolimod on NK cell maturation, differentia-
tion, and activation were investigated longitudinally (base-
line vs. treatment) by flow cytometry. Blood samples were 
obtained at baseline visit (visit 0) and 1 month (visit 1), 
3 months (visit 2), 6 months (visit 3), and 12 months (visit 
4) after treatment initiation. The primary endpoint was the 
degree of NK cell maturation, defined as the ratio of imma-
ture NK cells/total NK cells (percentage) before fingolimod 
treatment and after 12 months of treatment. Secondary end-
points included NK cell frequency, percentage of immature 
NK cells/total NK cells, and degree of NK cell activation 
and maturation at all time points. Clinical secondary end-
points included the number of relapses, the disability profile 
(determined by the EDSS [73]), and side effects determined 
by the numbers of adverse events and infections.
Study Drug Application
Fingolimod in 0.5mg capsules was administered orally once 
daily for a period of 12 months. The treatment phase began 
at the baseline visit within 4 weeks after the screening visit. 
Treatment exactly complied with the approved label, dose, 
application, frequency, and safety monitoring. All regular 
study visits coincided with the regular treatment monitor-
ing visits, but included larger samples of venous blood (ca. 
40 ml).
Sample Collection and Flow Cytometry
Heparinized peripheral blood samples were collected during 
study visits. Peripheral blood mononuclear cells (PBMCs) 
were isolated by density gradient centrifugation (Biochrom 
GmbH, Germany) according to the manufacturer’s instruc-
tions as described previously [56], and were then cryopre-
served in liquid nitrogen for later analysis. All samples of 
the same patient (different time points) were processed and 
analyzed simultaneously.
For the characterization of NK cell subpopulations, 
defrozen PBMCs were washed and incubated with human 
Fc fragments (Miltenyi Biotec, Germany) to block unspe-
cific antibody binding, followed by the incubation with anti-
CCR7-BV421, anti-NKG2C-AlexaFlour488, anti-DNAM-1/
CD226-PerCP/Cy5.5, anti-CD158a/h-PE, anti-CD56-PE/
Dazzle594, anti-NKG2A/CD159a-PE/Cy7, anti-CD94-APC, 
anti-Lin( CD3, CD19, CD14, CD20)-Alexa700, anti-CD16-
APCfire750, anti-NKG2D-BV510, anti-CX3CR1-BV605, 
anti-NKp46-BV650 and anti-CD127-BV785. Viable cells 
were identified with “LIVE/DEAD™ Fixable Dead Cell 
Stain Kits “ (Thermofisher). Data were acquired at Cytoflex 
LX flow cytometer (Beckman Coulter).
Clinical Data Collection and Analysis
As fingolimod shows a steady-state blood concentration 
only after approximately 2 months of treatment [74], the 
first 3 months of treatment were not considered when assess-
ing clinical effects. Effect of treatment on relapse rates was 
therefore evaluated by comparing the annualized rate of 
relapses during treatment (from month 3 to 12) to the annu-
alized rate in the 24 months prior study.
Relapses were defined as either the occurrence of new 
neurological symptoms or the recurrence or worsening of 
previously existent symptoms/signs at least 30 days after 
the beginning of a previous demyelinating event. The symp-
toms/signs had to last at least 24 h and had to occur indepen-
dently of fever or acute infections. The course of MS-related 
disability determined by EDSS [73] was evaluated by com-
paring the EDSS from month 3 and month 12.
Treatment response was defined as the absence of EDSS 
increase from month 3 to month 12 and decrease in ARR 
when comparing the ARR from month 3 to month 12 on-
treatment with the 24 months pre-treatment ARR. Non-
response was defined as EDSS increase from month 3 to 
month 12 and/or stable ARR or increase in ARR when com-
paring the ARR from month 3 to month 12 on-treatment with 
the 24-month pre-treatment ARR. If no relapse occurred dur-
ing the study and 24 months prior to study and the EDSS 
did not increase from moth 3 to month 12, the patient was 
considered a responder.
Flow Cytometry Data Analysis and flowSOM‑Based 
Unsupervised Analysis
The flow cytometry data were first analysed unblinded using 
FlowJo software 10.4 (TreeStar). Thereafter, a multidimen-
sional unsupervised analysis was conducted using Cyto-
bank (www. cytob ank. org). Fluorescent minus one (FMO) 
stainings were used as controls. The applied gating strategy 
is shown in Fig. 1. From the 84 acquired data points, 13 
measurements were excluded during the analysis process 
due to poor sample quality (very high number of dead cells 
or debris) or defective acquisition. These samples were 
excluded before the initiation of the analysis.
Expression of a given marker was determined either by 
percentage of fluorescence positive cells or by using the 
mean fluorescence intensity (MFI). In the latter case, a 
change in the MFI (Δ MFI) was calculated by subtracting 
the MFI of the FMO-control from the FMI of the specific 
marker.
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In addition, to avoid biased analysis based in pre-determined 
populations, we performed a multidimensional unsupervised 
analysis using the FlowSOM algorithm [75]. For that, all com-
pensated files were transferred to the Cytobank and scaled in 
this program. Events (cells) from all included patients and all 
visits were assigned to a self-organizing map. Events with simi-
lar properties were aggregated in one of different 81 clusters. A 
minimal spanning tree visualized similar clusters in the same 
branch of this tree. Clusters with similar properties were then 
further integrated within 15 final metaclusters (MCs). To assess 
effects of treatment on NK cell clusters, MC percentage at base-
line visit and after 12 months of therapy were compared. Next, 
a qualitative analysis of differences of the MCs in responders 
and non-responders was conducted.
Statistical Analysis
Data of primary and secondary endpoints and the MCs 
were analyzed using an exploratory approach and descrip-
tive statistics (frequency of parameters, median). To assess 
the primary endpoint, status of NK cell maturation (ratio 
immature NK cells per total NK cells as a percentage) before 
treatment and after 12 months of treatment was compared. 
Secondary immunological endpoints (NK cell frequency, 
Fig. 1  Gating strategy. Artefacts caused by poor flow were elimi-
nated in a time vs. scatter plot; afterwards, dead cells as well as cell 
clumps or doublets were excluded; to disregard cell debris, only 
events > 500,000 on the FSC-A scale were included in further anal-
ysis; lymphocyte population was determined by its characteristic 
morphology in FSC-A vs. SSC-H plot; T, B, NKT cells and mono-
cytes were excluded from the analysis by staining for CD3, CD19, 
CD14, or CD20, respectively. ILCs were described as lineage-
negative,  CD56−CD127+ cells. NK cells were defined as lineage-
negative  CD56+ cells. The  CD56+ cells were further discriminated 
in  CD56dim (a_1) and  CD56bright (a_2) cells. The expression of the 
other markers of interest (CCR7, NKG2C, DNAM-1, CD158a/h, 
NKG2A, CD94, NKG2D,  CX3CR, NKp46) were analysed consider-
ing both, all NK cells and the subgroups  (CD56dim and  CD56bright). 
NK cells were also subcategorized according to CD16 expression in 
 CD56brightCD16− (b_1),  CD56brightCD16+ (b_2),  CD56dimCD16− 
(b_3), and  CD56dimCD16+ (b_4). FSC forward scatter, SSC side scat-
ter, -H pulse height, -A pulse area
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ratio immature NK cells per total NK cells, as well as the 
frequency of NK cell activation and functional markers) 
were evaluated for the whole treatment period. Additionally, 
the frequency of the MCs from the unsupervised clustering 
analysis was evaluated for all time points. Non-parametric 
(pairwise exact Wilcoxon) analysis was performed to com-
pare (univariately) immune subsets before treatment and 
after 12 months of treatment. In order to test for systematic 
changes over time, markers of special interest with a sig-
nificant Wilcoxon result were included in a nonparametric 
analysis of longitudinal data (nonparametric MANOVA) 
[76]. Univariate post hoc Wilcoxon tests after global test-
ing were used to check for significant differences in certain 
clinically interesting time points.
Generalized estimating equations (GEE) were applied to 
test for potential associations between clinical parameters 
and changes in immunological endpoints over time. Differ-
ent GEE models were examined with number of infections, 
number of relapses, and frequency of  CD56bright, MC4, and 
 CD56dimCD94low cells as independent influencing factors. 
Based on our previous experiences in neurology [77], we 
used an autoregressive model of 1st order for the correla-
tion matrix.
Tests should be seen as exploratory data analysis. There-
fore, all p-values have to be understood as exploratory ones. 
For that reason, no adjustments for multiple testing were 
conducted. Statistical significance was defined as p < 0.05. 
Calculations were performed using IBM© SPSS© Statis-
tics, Version 25, © Copyright 1989, 2016 SPSS Inc., an 
IBM Company and the R Project for Statistical Computing, 




Twenty-one patients were screened and included in this 
study. Three patients terminated fingolimod treatment early 
due to a significant elevation of liver enzymes (2 patients) 
or severe lymphocytopenia (1 patient) and therefore dropped 
out. Another patient developed severe lymphocytopenia 
(grade 4 toxicity) before the last visit; for this patient, the 
data of only 4 time points were analyzed. Data of another 
patient were removed from the analysis because of the poor 
quality of the frozen blood samples.
The final analysis included therefore 16 patients treated 
daily for 12 months and one patient treated for 10 months. 
Demographic baseline data are displayed in Table  1. 
Females accounted for 65% of the cohort; the mean age at 
screening was 41 years; the mean MS duration was 10 years. 
The median EDSS score at treatment start was 2.0. Fifteen 
(88%) of the 17 patients received previous treatment with 
other disease-modifying drugs. Based on the response cri-
teria described in “Methods,” seven patients (41%; 2 males, 
5 females) were classified as non-responders.
From the patients included in the analysis, 24% (n = 4) 
suffered from one or more relapses during the study. A total of 
18% (n = 3) showed an increase in the ARR calculated 
from month 3 to month 12 on-treatment compared with 
the 24-month pre-treatment ARR. Median EDSS remained 
stable from visit 2 (third month of treatment) to the last 
visit after 12 months of treatment. In 35% (n = 6), an EDSS 
increase was observed. Thus, relapses and/or EDSS increase 
were observed in seven patients that for hypothesis generat-
ing analyses were considered as non-responders.
Serious adverse events were reported in three patients, 
namely elevated liver enzymes, herpes zoster, and urosepsis 
with subsequent aggravation of MS-symptoms. No 
serious adverse events resulted in hospitalization, death, or a 
permanent disability. Fourteen infection-related adverse events 
were recorded, seven in the responder group, affecting four 
patients, and seven in the non-responders, that affected five 
out of the seven patients. Therefore, as shown in Table 2, the 
number of patients affected by infections was higher in the 
non-responder group (71%) than in the responder group (40%).
Effects of Fingolimod on Immature/Mature NK Cell 
Fractions
NK cell markers were analysed according to the gating strat-
egy shown in Fig. 1. The expression of maturation markers 
was analysed considering all NK cells or the  CD56dim and 
 CD56bright fractions separately as displayed in Fig. 1. The 
following statistical analyses should be seen as exploratory 
data analysis; therefore, all p-values are to be understood as 
exploratory ones.
Figure  2A shows that the frequency of circulating 
 CD56+ NK cells increased during treatment (MANOVA 
p = 0.003), from 8.74% before treatment to 28.90% after 
1 month (Wilcoxon test p = 0.005) up to 40.05% at month 
12 (Wilcoxon test p < 0.001).
Table 1  Demographic characteristics
SD standard deviation
n = 17
Age (in years, mean ± SD) 40.8 ± 10.0
Females (n (%)) 11 (64.7)
Interval from MS onset to baseline
(in years, mean ± SD)
10.1 ± 6.7
Annualized relapse rate (ARR)
24 months before baseline
0.68
EDSS score at baseline (median (range)) 2.0 (0.0–6.0)
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Further, we observed a fingolimod-associated reduc-
tion of  CD56bright NK cells over time (MANOVA 
p = 0.0000009) from 9.30% at baseline to 3.83% after 
1  month (Wilcoxon test p < 0.001) and 3.56% after 
12 months of treatment (Wilcoxon test p < 0.001) (Fig. 2B). 
However, as shown in Fig. 2C, within the  CD56dim popula-
tion only, the fraction of circulating  CD16+  CD56dim NK 
cells increased during treatment from baseline median 
59.30 to 77.43% after 12 months of fingolimod intake (Wil-
coxon test p = 0.042). Additionally, the analysis of ILCs, 
defined as  CD56−CD127+ cells, revealed a mild decrease 
over the treatment period from 0.17 to 0.12% (Wilcoxon 
test p = 0.01) (data not shown).
Further, we focused on the fully mature fractions, that are 
 CD94low [78] and express KIR, but no NKG2A [79, 80]. We 
observed an increase of fully mature  CD56dimCD94low over 
time (MANOVA p = 0.014) (Fig. 3A) from 32.65% at base-
line to 44.60% after 12 months of treatment (Wilcoxon test 
p = 0.008). In the same line,  NKG2A−KIR+  CD56dim NK 
cells increased slightly from 19.30% at treatment initiation 
to 20.85% after 12 months of fingolimod intake (Wilcoxon 
test p = 0.013) (Fig. 3B).
Table 2  Clinical outcomes
Relapses All patients (n = 17) Responder (n = 10) Non-responder (n = 7)
Patients with confirmed relapse from visit 2 to treatment termination (n 
(%))
4 (23.5) 0 (0.0) 4 (57.1)
1 relapse (n(%)) 2 (11.8) 0 (0.0) 2 (28.6)
2 relapses (n(%)) 2 (11.8) 0 (0.0) 2 (28.6)
Annualized relapse rate (ARR) 0.47 0 1.14
EDSS
Patients with EDSS increase from visit 2 to treatment termination (n (%)) 6 (35.3) 0 (0.0) 6 (85.7)
Change from visit 2 to visit 4 (median (range))  0.0 (− 1.5–1.5)  − 0.5 (− 1.5–0)  0.5 (0.0–1.5)
Infections
Patients with infections from visit 2 to treatment termination (n (%)) 9 (53.0) 4 (40.0) 5 (71.4)
Number of infections from visit 2 to treatment termination 14 7 7
Fig. 2  Effect of fingolimod 
therapy on the expression 
of CD56 and CD16. Repre-
sentative FACS plots displaying 
fingolimod-induced changes 
over time in several NK cell 
populations are depicted on 
the left-side. Box-and-whisker 
plots show the corresponding 
quantification for all patients at 
all timepoints. a Analysis of all 
NK cells over time. b Analy-
sis focusing on  CD56bright. c 
Analysis of NK cells accord-
ing to their CD56 and CD16 
expression: The  CD56dimCD16+ 
population is framed. The cor-
responding box-and-whisker 
plot shows changes overtime 
affecting the  CD56dimCD16+. 
MANOVA *p ≤ 0.05; 
**p ≤ 0.01; ***p ≤ 0.001; 
exact Wilcoxon test #p ≤ 0.05; 
##p ≤ 0.01; ###p ≤ 0.001; SSC 
side scatter, -A pulse area
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Thus, the proportion of highly mature NK cells increased 
after 1 month of treatment and remained elevated during 
the treatment period of 12 months (overview supplementary 
Table 2).
Activation and Chemotactic Capacity of NK Cells 
Under Fingolimod Treatment
To evaluate the proportion of NK cells with activating or 
migration-mediating receptors during the treatment with 
fingolimod, we examined the expression of the chemokine 
receptors CCR7 and  CX3CR1, as well as the inhibition 
marker NKG2A and the activation markers NKp46, DNAM-
1, NKG2D, and NKG2C.
Fingolimod treated patients showed a decreased propor-
tion of both  CCR7+ and  CX3CR1+  CD56dim NK cells in 
peripheral blood. As shown in Fig. 4A, the CCR7 express-
ing  CD56dim NK cells decreased from treatment initiation 
to the later visits (MANOVA p = 0.0032). The fraction of 
 CCR7+  CD56dim NK cells decreased from 5.30% at base-
line to 2.46% after 12 months of treatment (Wilcoxon test 
p = 0.007) (Fig. 4A). We observed a trend in the decrease 
in fluorescence intensity of  CX3CR1 on  CD56dim NK cells 
(p = 0.056) (supplementary Fig. 1B). No change in CCR7 or 
 CX3CR1 was observed in  CD56bright NK cells (supplemen-
tary Fig. 1A, 1B).
Furthermore, the proportion of the  CD94+NKG2A+ NK 
cells was reduced from 51.60 to 47.60% at the 12-month visit 
(Wilcoxon test p = 0.004). The frequency of  CD94+NKG2A+ 
cells also decreased in both  CD56dim and  CD56bright NK 
cells after 1 month of treatment and remained low during 
the entire treatment period (supplementary Fig. 1C).
Next, we analysed changes in the percentage of NK 
cell activation receptors. While the ratio of  NKp46+ and 
DNAM-1+ NK cell subpopulations was consistently reduced 
after 1 month of fingolimod intake, we observed no sig-
nificant changes in  NKG2D+ and  CD94+NKG2C+ NK cells 
(supplementary Fig. 1D, 1E, 1F, 1G). The proportion of 
NKp46 expression only decreased in  CD56dim NK cells, 
while  CD56bright NK cells were not affected (supplemen-
tary Fig. 1D). While the decrease from baseline (median 
frequency: 18.90%) to 12 months of treatment (median fre-
quency: 15.80%) was significant (Wilcoxon test p = 0.007) 
in the  CD56dimNKp46+ cells, no alteration over the entire 
treatment period was observed (Fig. 4B).
On the other hand, the ratio of DNAM-1 express-
ing  CD56bright decreased during the observation period 
(MANOVA p = 0.0036) (Fig. 4C). In line with these find-
ings, we could also evaluate a significant decrease in the 
proportion of DNAM-1 in  CD56dim NK cells comparing 
baseline to 12 months (Wilcoxon test p = 0.035) (supple-
mentary Fig. 1E).
Thus, fingolimod may affect NK cell function by promot-
ing a reduced fraction of activation receptors expressing NK 
cells. This was observed for the entire NK cell population 
and also for the  CD56bright and  CD56dim fractions (overview 
supplementary Table 2).
Unsupervised Multidimensional Analysis 
of the Effect of Fingolimod on NK Cell 
Subpopulations
To investigate whether a so far undescribed fraction of circu-
lating NK cells increases in fingolimod treated patients, the 
high-dimensional data set was further explored by means of 
the unsupervised clustering algorithm FlowSOM. FlowSOM 
clusters and reduces the dimensionality by displaying the 
data of all markers and patients in one self-organized map 
(SOM) [75]. From 83 flow cytometry files of all patients 
included in this study, which were manually pre-gated for the 
Fig. 3  Effect of fingolimod 
therapy on NK cell maturation 
markers. Representative FACS 
plots and the corresponding 
quantification are depicted 
on the left- and right-side, 
respectively. a Frequency of 
 CD56dimCD94low cells from 
the CD56 fraction. b Quanti-
fication of the  NKG2A−KIR+ 
cells from the  CD56dim frac-
tion. MANOVA *p ≤ 0.05; 
**p ≤ 0.01; ***p ≤ 0.001; 
exact Wilcoxon test #p ≤ 0.05; 
##p ≤ 0.01; ### p ≤ 0.001
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 CD56+ NK cell (as shown in Fig. 1), a minimum-spanning 
tree (MST) was generated. Clusters with cells characterized 
by similar phenotypes are depicted in the same branch of the 
tree. Data was merged into a total of 81 clusters and further 
aggregated into 15 MC. Figure 5A illustrates the MST by 
displaying the median CD56 signal intensity for each cluster 
node coded by colour. Cluster size reflects the number of 
events included in it. Here,  CD56bright NK cell cluster (black 
frame) can be easily identified and showed a decrease over 
time (Fig. 5A).
The comparison of all MC revealed that three inter-
related MC (MC6, 13, and 15) decreased significantly 
comparing baseline and 12 months of treatment (Wil-
coxon test p = 0.001). As shown in Fig.  5B, all three 
MCs are characterized by a high expression of  CD56bright 
(orange or red cluster nodes). While the baseline-
frequency of MC6, MC13, and MC15 was 11.84%, it 
decreased to 5.90% after 1 month and further decreased 
to 4.00% after 12 months of treatment (Fig. 5C). Unsu-
pervised analyses confirmed our previous results that 
the proportion of NK cell with bright CD56 expression 
decreased during treatment.
Further, we identified a significant increase in the fre-
quency of MC4, containing  CD56dim expressing NK cells 
and a decrease in the frequency of MC11, containing NK 
cells with different levels of CD56 expression (Fig. 5B). 
The MC4 fraction expanded significantly from a baseline 
median frequency of 29.59 to 43.45% after 12 months of 
therapy (Wilcoxon test p = 0.01), while the MC11 fraction 
slightly decreased from median 5.34 to 4.90% (Wilcoxon 
test p < 0.001) (Fig. 5C).
To define the phenotype of cells within a MC, median 
expression of all analysed markers with a colour spectrum 
scaled per marker from minimum to maximum fluores-
cence intensity are depicted in Fig. 6A. While MC4 cells 
are  CD1 6+ +K IR +/− NK G2A − CD9 4− CC R7 +/− CX 3 CR1 +/ −N 
KG2 C− NK G2D + NKp 46−DNAM-1++CD127+, NK cells 
of the MC11 are  CD1 6+ KI R− NK G2A ++ CD 94 ++ CCR 
7+ /− CX 3C R1 +/− NK G2C − NKG 2D++NKp46++DNAM1++ 
 CD127+/−. Thus, in comparison to MC4, MC11-NK 
cells express lower levels of CD16, KIR, and CD127 and 
higher levels of NKG2A, CD94, NKG2D, and NKp46 and 
could be considered as an intermediate mature NK cell 
population.
Next, data from patients considered as responders and 
non-responders were mapped to the MST separately. The 
frequency of the different MCs depicted with a colour 
scale at baseline, as well as after 6 and 12 months of treat-
ment, is represented in Fig. 6B. We observed a higher 
frequency of the  CD56bright MCs (MC6, 9, 13, 15) and 
the  CD127+ MC2 in the non-responders compared to the 
responders at baseline visit. After treatment initiation, 
these MCs seem to decrease in both non-responders and 
responders and converge to same levels.
Fig. 4  Effect of fingolimod 
therapy on NK cell activation 
and chemotactic responses. 
Representative FACS plots and a 
histogram displaying fingolimod-
induced changes over time of 
CCR7 (a), NKp46 (b), and 
DNAM-1 (c) are depicted on 
the left-side. Box-and-whisker 
plots on the right-side show the 
corresponding quantification 
for all patients at all time points. 
MANOVA *p ≤ 0.05; **p ≤ 0.01; 
***p ≤ 0.001; exact Wilcoxon 
test #p ≤ 0.05; ##p ≤ 0.01; 
###p ≤ 0.001; SSC side scatter, 
-A pulse area, FMO fluorescence 
minus one, MFI median fluores-
cence intensity
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Fig. 5  FlowSOM unsupervised 
clustering of  CD56+ NK cells 
in fingolimod treated patients. 
The FlowSOM clustering 
was performed by analys-
ing the expression of CCR7, 
NKG2C, DNAM-1, 158a/h, 
CD56, NKG2A, CD94, CD16, 
NKG2D,  CX3CR1, NKp46, 
and CD127 on each cell for 
all samples. Cells with similar 
characteristics are merged into 
one cluster, shown as individual 
nodes in the minimum-spanning 
tree (MST). Clusters with 
similar conditions are pictured 
close to each other. The median 
fluorescence intensity of each 
marker is visualized by the col-
ours; red represents high expres-
sion, while blue represents low 
marker expression. The colour 
around each cluster shows the 
MC this cluster belongs to. 
The cluster size represents the 
number of cells that integrates 
this cluster. a CD56 expres-
sion on NK cells at treatment 
start (0 months) and after 6 and 
12 months of treatment. The 
 CD56bright clusters are framed. 
 CD56bright clusters decreased 
in size, while  CD56dim cluster 
increased from treatment start to 
6 and 12 months of treatment. 
b Expression of different mark-
ers. The MCs with significant 
changes are framed. The contin-
uous line encloses the MC that 
increased, and the dashed line is 
around the MCs that decreased 
over the treatment period. c 
Box-and-whisker plot of the 
percentage of MC4 per total NK 
cells, MC11 per total NK cells, 
and the sum of MC6, 13 and 15 
(all MC are  CD56bright) per total 
NK cells of all included patients 
at treatment start (0 months) 
and 1, 3, 6, and 12 months after 
treatment. MANOVA *p ≤ 0.05; 
**p ≤ 0.01; ***p ≤ 0.001; 
exact Wilcoxon test #p ≤ 0.05; 
##p ≤ 0.01; ###p ≤ 0.001; MC 
metacluster
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Longitudinal Association of Fingolimod‑Induced 
Changes in NK Cell Subpopulations with Clinical 
Outcome Parameters
Further, we performed a hypothesis-driven analysis, 
in which three different NK cell subpopulations were 
investigated as independent variable for associations 
with clinical endpoints (number of infections, num-
ber of relapses, number of adverse events, EDSS, and 
response) within the 12 months of treatment. The inde-
pendent variable were  CD56bright cells, a regulatory, low 
cytotoxic NK cell subpopulation [81],  CD56dimCD94low 
cells, a mature subpopulation with low regulatory, but 
high cytotoxic capacity [78] and MC4 cluster, a yet 
undescribed NK cell cluster that showed a significant 
fingolimod-induced increase in the previous unsuper-
vised clustering analysis.
Generalized estimating equation (GEE) analysis revealed 
interesting initial data. We measured an inverted correla-
tion between changes in  CD56dimCD94low and number of 
infection (Table 3), indicating that an increase in propor-
tion of one percent of this population correlates with a 
decreased risk for an infections by 3.7% (odds ratio = 0.963; 
95% confidence interval = 0.939–0.988, p = 0.004). In 
addition, a decrease of the  CD56bright fraction correlated 
with a relapse risk increase (decrease by 1% was associ-
ated with an increase of the risk for a relapse by 25.9%, 
odds ratio = 0.741; 95% confidence interval = 0.556–0.998, 
p = 0.041)]. No significant correlations between the three 
NK cell populations and number of AEs, EDSS, or response 
were found.
To summarize, an increase in the fraction of 
 CD56dimCD94low and  CD56bright NK cell populations was 
associated with a reduced number of infections and with a 
reduced number of relapses, respectively.
Fig. 6  Heatmaps of the MC. a Heatmap of all MCs on the basis of 
the median expression of 12 markers with a colour spectrum scaled 
per marker from minimum to maximum fluorescence intensity. The 
continuous black line encloses the MC4 that increased significantly 
over time; dashed black lines define the MCs that decreased signifi-
cantly during the treatment (MC 6, 11, 13, 15). b Direct comparison 
of MC frequencies in responders (“R,”  dark grey) and non-responders 
(“N,”  light grey) in a heatmap for baseline and the visits after 6 and 
12  months of treatment. Each column represents the MC frequen-
cies of one patient for one specific timepoint during the therapy. To 
improve the comparability between the different MCs and accounting 
for subject-specific ranges, we showed the frequencies with a row z 
score normalization (per sample across all MCs).  CD56bright MCs 
framed. MC metacluster
Table 3  Longitudinal association of clinical outcome parameters and fingolimod-related NK cell profile
Results for two separate multivariate generalized estimating equation (GEE) analyses, using the “number of infection” or “number of relapses” 
as dependent variables, respectively. As independent parameters  CD56bright, MC4 and  CD56dimCD94low were used in both models. Analyses 
were conducted to check for prediction of the clinical parameters by alteration of the immune populations. Values in bold indicate significant 
correlations
Coefficient (95% CI) p-value Odds ratio (95% CI)
Dependent variable: number of infections
Independent variable: Change in  CD56bright  −0.080 (−0.169–0.008) 0.073 0.923 (0.845–1.008)
Change in MC4  −0.010 (−0.040–0.020) 0.503 0.990 (0.960–1.020)
Change in  CD56dimCD94low  −0.037 (−0.063 to −0.012) 0.004 0.963 (0.939–0.988)
Dependent variable: number of relapses
Independent variable: Change in  CD56bright  −0.300 (−0.587–0.012) 0.041 0.741 (0.556–0.988)
Change in MC4 0.037 (−0.005–0.080) 0.085 1.038 (0.995–1.083)
Change in  CD56dimCD94low 0.043 (−0.007–0.094) 0.093 1.044 (0.993–1.099)
Fingolimod Therapy in Multiple Sclerosis Leads to the Enrichment of a Subpopulation of Aged…
1 3
Discussion
This pilot study aimed to determine the effects of 
12 months of fingolimod treatment on frequency and phe-
notype of circulating NK cells in a cohort of MS patients 
in the context of an exploratory flow cytometry analysis.
We observed an increase of NK cell fraction within the 
lymphocytes over the treatment period (Fig. 2A), which is 
consistent with previous reports [60–62, 64, 65, 68, 69]. 
Hjorth et al. [69] demonstrated a decrease in number of cir-
culating lymphocytes in fingolimod treated patients, while 
NK cell numbers were not affected. NK cells, contrary to 
T and B cells, only express low levels of the major fingoli-
mod target  S1P1 receptor [23, 24]. Thus, the increase of NK 
cell frequency observed in our study may result from the 
decreased number of circulating adaptive lymphocytes that, 
in contrast to NK cells, are broadly sequestered within the 
secondary lymphoid tissue during fingolimod treatment [82].
Moreover, our study confirmed that fingolimod reduces 
the proportion of circulating ILCs [25] and led to a reduced 
proportion of the circulating immature  CD56bright NK cells 
and an increased proportion of the  CD56dim NK cell frac-
tion (Fig. 2B) [60, 63–65, 68]. Our longitudinal study also 
confirmed that these effects could be observed already after 
the first month of treatment and were maintained over 1 year 
of regular fingolimod intake. The decreased frequency of 
 CD56bright and the increased frequency of  CD56dim could be 
explained by their different forms of recirculation.  CD56bright 
may be more susceptible to sequestration within secondary 
lymphoid tissue (SLT) and  CD56dim to exit SLT, because 
contrary to the  CD56dim,  CD56bright cells express high lev-
els of the homing receptors L-selectin and CCR7 [83, 84] 
and, in addition,  CD56dim cells appear to express high levels 
of  S1P5 receptors, that appear to be resistant to fingolimod 
effects in vivo [24, 60, 63].
Moreover, we analysed additional phenotypic markers 
in the peripheral blood that included CD16, CD94, or the 
KIRs (Fig. 3). Highly mature  CD56dim NK cells are char-
acterised by low CD94, low NKG2A, and high KIR levels, 
and by a low IFN-gamma, but a high granzyme B and 
perforin production [78, 79]. Here, we showed that over 
12 months of treatment, the fraction of  CD56dimCD94low 
was significantly enriched in the circulation, suggesting 
not only a predomination of mature  CD56dim but rather a 
continuous shift within the  CD56dim population towards 
fully maturation and differentiation. These findings were 
also in line with a mild increase in the frequency of mature 
 CD56dimNKG2A−KIR+ after fingolimod initiation.
Our data further revealed that under fingolimod therapy, 
NK cells showed an altered functional receptor profile, with 
a lower percentage in expression of CCR7 and  CX3CR1, 
the inhibitory receptor NKG2A, as well as the activating 
receptors NKp46 and DNAM-1 (Fig.  4; supplementary 
Fig. 1). Effects on CCR7 were already reported in treated 
patients versus untreated MS patients and healthy donors 
[60].  CD56bright NK cells are up to 60% positive for CCR7 
[83] and represents around 95% of the lymph node NK cells 
[85], while only 5% of  CD56dim NK cells are  CCR7+ [83]. 
Our data also confirmed that around 5% of the  CD56dim 
express CCR7 at baseline, and that this small population, 
with probably an intermediary mature phenotype, seems to 
be also sequestered within the lymph nodes during treatment.
Further, we observed that the fraction of  CX3CR1+ NK 
cells is also diminished during treatment (supplementary 
Fig. 1). We previously showed that  CX3CR1 is expressed on 
mature NK cells [86] and that MS patients have a reduced 
proportion of circulating  CX3CR1+ NK cells, although 
increased frequency of peripheral  CX3CR1+ NK cells cor-
relates with an enhanced MS activity [40]. Since most of 
the patients of our cohort were stable during the study, the 
decreasing  CX3CR1 levers might reflect the therapy success.
We also measured a decrease in the frequency of NKp46 
and DNAM-1 in peripheral blood. DNAM-1 decrease 
in fingolimod treated patients might result in a reduced 
anti-tumour capacity. In MS patients, a reduced ability to 
kill activated  CD4+ T-cells via activation of DNAM-1 is 
described [41]. DNAM-1+ NK cells enriched within the 
SLT may kill even more efficiently those autoreactive T cells 
[41]. In the context of our study, the decrease of DNAM-1 in 
the peripheral blood could be explained by the shift of NK 
cells towards a fully differentiated [87] or even exhausted 
[88] profile. Both markers, DNAM-1 and NKp46, play an 
important role in the innate immune response against human 
cytomegalovirus infected dendritic cells; NKp46 is further-
more involved in recognition and defence of several other 
viruses [89–92]. A relative reduction of these receptors in 
the peripheral blood might lead to a higher susceptibility of 
fingolimod treated patients for viral infections.
Further, using the flow cytometry data combined with an 
unsupervised clustering, we identified 15 NK cell clusters that 
changed in frequency during fingolimod therapy and compared 
these alterations in responders and non-responders. Although 
the sample size is very limited, we decided to conduct an 
exploratory analysis based on response to provide a basis for 
comparison with studies that reported on associations between 
certain NK cell subtype and clinical outcome. We confirmed a 
significant reduction in the ratio of  CD56bright clusters and an 
alteration in two specific  CD56dim NK cell clusters (MC4, 11) 
(Fig. 5). During treatment only the fraction of MC4 increased, 
while MC11 decreased significantly (Fig. 6A). Compared to 
MC11, MC4 is characterized by a low expression of CD56, 
CD94, NKG2A, and NKG2D, but a higher expression of 
CD16 and KIR. These results indicate that MC4 may repre-
sent a fully mature or even exhausted cluster predominant in 
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fingolimod treated patients, while MC11 represents an inter-
mediate mature MC, which decreased with the treatment.
In our GEE analysis, no correlation was observed between 
MC4 and treatment response or clinical outcomes. How-
ever, we did observe an association between an increased 
frequency of  CD56dimCD94low (characteristic for MC4 and 
MC8) and a lower number of infections.  CD56dimCD94low 
cells are cells with great capacities to produce intracellular 
perforin and granzyme B [78]. In the same line, decreased 
 CD56bright and  CD56dimCD94low frequencies were inversely 
associated with an increased number of relapses. These 
results are certainly interesting but need further validation 
due to small patient numbers in our study.
In our cluster analysis,  CD56bright frequency was higher at 
baseline in patients considered as non-responders compared 
to those considered as responders. However, after fingolimod-
treatment, frequencies of  CD56bright and  CD56dim were com-
parable in both groups; thus, the decrease in  CD56bright MCs 
and accordingly the increase in  CD56dim fraction were more 
pronounced in the non-responder patients (Fig. 6). Although 
these data are preliminary due to the limited sample size, 
they may indicate that a strong treatment-related reduction 
of the  CD56bright cell fraction is associated with the lack of 
response. In fingolimod treated patients, high frequency of 
the  CD56bright fraction has been associated with stable mag-
netic resonance imaging [64] and also with response, using 
an achieved NEDA(no evidence of disease activity)-3 and 
NEDA-4 status as response criteria [65]. An association 
between  CD56bright cells and reduced relapse rate has been 
also observed in MS patients during late pregnancy [93]; 
and in patients treated with daclizumab,  CD56bright increase 
predicted a reduced number of gadolinium enhancing lesions 
[54]. Thus, our data may also suggest that an increased frac-
tion of circulation  CD56bright could be associated with treat-
ment benefits in MS [64].  CD56bright NK cells that are not 
reaching the blood are probably captured in the SLT [63]. 
Accumulation of  CD56bright in the SLT could facilitate inter-
actions with T cells and dendritic cells [94, 95]. Moreover, the 
high IL-7 expression within the SLT may promote NK cell 
surveillance [96]. It is therefore conceivable that  CD56bright 
can be safely stored within SLT and regulate locally adap-
tive autoimmune response, or exit the SLT strengthened 
when needed in the periphery. The latter possibly happens 
in patients who benefit from fingolimod treatment, as they 
show a lower decrease of  CD56bright cells in the peripheral 
blood during treatment [64]. Furthermore, SLT is described 
as a compartment of NK cell maturation [97, 98]. Thus, the 
arrest of NK cells in SLT might lead to further maturation of 
these cells.
Our data suggest an increased frequency of fully differ-
entiated or even “exhausted” long-lived NK cells in the cir-
culation of fingolimod-treated MS patients in the peripheral 
blood. Interestingly, although the limited amount of patient’s 
material did not allow to perform functional tests in vitro, 
the profile of this NK cell cluster predominant in fingoli-
mod treated patients resembles the phenotype described in 
elderly healthy people. With age,  CD56dim NK cell frac-
tion and the expression of KIR increase [99–102], while the 
 CD56bright fraction and expression of NKG2A and CD94 
decrease [101, 103]. In addition, and also in line with our 
results, a reduction in NKp46 and DNAM-1 has also been 
observed during age [100, 102, 104], while CD16 expression 
remains unchanged [103, 105]. This phenotype reflects a 
NK cell subgroup with diminished NK cytotoxicity that may 
underline the high risk of infections observed in fingolimod-
treated patients and also in elderly people [102, 106, 107]. 
Furthermore, it is imaginable that an enhanced fraction of 
“exhausted”  CD56dim NK cells may be accompanied by a 
diminished proportion of detrimental subtypes, contributing 
to an overall benefit for MS. However, further studies are 
needed to verify this hypothesis.
The small number of patients included in our study rep-
resents an important limitation, which has an impact on the 
power of our calculations, the balance on the selection of 
participants, and the detection of small but statistically sig-
nificant changes. Therefore, the conducted statistic should 
be understood as exploratory data analysis, and therefore, all 
p-values should be considered as exploratory ones. Moreo-
ver, our study design does not permit to establish causal rela-
tionships between changes affecting NK cells and the treat-
ment, since those changes could just reflect the natural MS 
progression. Another important limitation is that the study 
lacks an untreated MS control cohort, which, due to ethical 
reasons, was unfeasible in a 12-months longitudinal study. 
However, confirming our estimations, other studies com-
paring effects with cohorts of untreated patients or healthy 
controls did present similar NK cell alterations exclusively 
in fingolimod treated patients [60, 61, 63, 65]. On the other 
side, due to the longitudinal character of our study, samples 
were frozen after the different visits to permit the simul-
taneous analysis of all time points of each single patient. 
This may have advantages in reducing experimental errors, 
but has the disadvantage that absolute cell accounts cannot 
be determined. Changes in population’s frequency could be 
due to redistribution rather than depletion or emergence of 
particular subpopulations.
In conclusion, our study indicates that fingolimod not 
only affects the balance between  CD56dim and  CD56bright 
NK cells, but also seems to promote a shift to elderly NK 
cell clusters, which are probably less functional. Along 
with the well-described effects of fingolimod on the adap-
tive immune response, this impact on the innate response 
may support the increased risk of tumour development [108] 
and/or infections observed in fingolimod-treated patients. 
No association between a certain NK cell subtype and the 
treatment response could be demonstrated in this pilot study. 
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Nevertheless, our data suggests an association between the 
frequency of cytotoxic  CD56dimCD94low NK cells and lower 
infection risk.
Supplementary Information The online version contains supplemen-
tary material available at https:// doi. org/ 10. 1007/ s13311- 021- 01078-7.
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